8 References [1] K. A. Pkowitz, “AIDS: the ﬁrst 20 years,” New England Journal of Medicine, vol. 344, no. 23, pp. 1764–1772, 2001. [2] P. Piot, M. Bartos, P. D. Ghys, and N. Walker, “The global impact of HIV/AIDS,” Nature, vol. 410, no. 6831, pp. 968–973, 2001. [3] K. H. Mayer and K. K. Venkatesh, “Antiretroviral therapy as HIV prevention: status and prospects,” American Journal of Public Health, vol. 100, no. 10, pp. 1867–1876, 2010. [4] E. de Clercq, “Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV,” International Journal of Antimicrobial Agents, vol. 33, no. 4, pp. 307–320, 2009. [5] E. de Clercq, “Antiretroviral drugs,” Current Opinion in Pharmacology, vol. 10, no. 5, pp. 507–515, 2010. [6] G. C. Williams and P. J. Sinko, “Oral absorption of the HIV protease inhibitors: a current update,” Advanced Drug Delivery Reviews, vol. 39, no. 1–3, pp. 211–238, 1999. [7] E. Ojewole, I. Mackraj, P. Naidoo, and T. Govender, “Exploring the use of novel drug delivery systems for antiretroviral drugs,” European Journal of Pharmaceutics and Biopharmaceutics, vol. 70, no. 3, pp. 697–710, 2008. [8] C. Y. Wu and L. Z. Benet, “Predicting drug disposition via application of BCS: transport/absorption/ elimination inter- play and development of a biopharmaceutics drug disposition classiﬁcation system,” Pharmaceutical Research, vol. 22, no. 1, pp. 11–23, 2005. [9] M. A. Cosenza, M. L. Zhao, and S. C. Lee, “HIV-1 expression protects macrophages and microglia from apoptotic death,” Neuropathology and Applied Neurobiology, vol. 30, no. 5, pp. 478–490, 2004. [10] C. M. Bates, “HIV medicine: drug side eﬀects and interac- tions,” Postgraduate Medical Journal, vol. 72, no. 843, pp. 30– 36, 1996. [11] D. D. Richman, D. M. Margolis, M. Delaney, W. C. Greene, D. Hazuda, and R. J. Pomerantz, “The challenge of ﬁnding a cure for HIV infection,” Science, vol. 323, no. 5919, pp. 1304–1307, 2009. [12] C. Flexner, “HIV drug development: the next 25 years,” Nature Reviews Drug Discovery, vol. 6, no. 12, pp. 959–966, 2007. [13] R. D. Benz, “Toxicological and clinical computational analysis and the US FDA/CDER,” Expert Opinion on Drug Metabolism and Toxicology, vol. 3, no. 1, pp. 109–124, 2007. [14] P. Palumbo, H. Wu, E. Chadwick et al., “Virologic response to potent antiretroviral therapy and modeling of HIV dynamics in early pediatric infection,” Journal of Infectious Diseases, vol. 196, no. 1, pp. 23–29, 2007. [15] D. Woolfson, M. L. Umrethia, V. L. Kett, and R. K. Malcolm, “Freeze-dried, mucoadhesive system for vaginal delivery of the HIV microbicide, dapivirine: optimisation by an ANN,” International Journal of Pharmaceutics, vol. 388, no. 1-2, pp. 136–143, 2010. [16] N. Subramanian, A. Yajnik, and R. S. Murthy, “Artiﬁcial neural network as an alternative to multiple regression analysis in optimizing formulation parameters of cytarabine liposomes,” AAPS PharmSciTech, vol. 5, no. 1, p. E4, 2004. [17] J. F. Contrera, E. J. Matthews, N. L. Kruhlak, and R. D. Benz, “Assessment of the health eﬀects of chemicals in humans: I. QSAR estimation of the maximum recommended therapeutic dose (MRTD) and no eﬀect level (NOEL) of organic chemicals based on clinical trial data,” Current Drug Discovery Technolo- gies, vol. 1, no. 1, pp. 61–76, 2004. Computational and Mathematical Methods in Medicine [18] J. Ro¨ling, H. Schmid, M. Fischereder, R. Draenert, and F. D. Goebel, “HIV-associated renal diseases and highly active antiretroviral therapy-induced nephropathy,” Clinical Infectious Diseases, vol. 42, no. 10, pp. 1488–1495, 2006. [19] Y. Sun, Y. Peng, Y. Chen, and A. J. Shukla, “Application of ar- tiﬁcial neural networks in the design of controlled release drug delivery systems,” Advanced Drug Delivery Reviews, vol. 55, no. 9, pp. 1201–1215, 2003. [20] E. J. Matthews, N. L. Kruhlak, R. D. Benz, and J. F. Contrera, “Assessment of the health eﬀects of chemicals in humans: I. QSAR estimation of the maximum recommended therapeutic dose (MRTD) and no eﬀect level (NOEL) of organic chemicals based on clinical trial data,” Current Drug Discovery Technolo- gies, vol. 1, no. 1, pp. 61–76, 2004. [21] J. F. Blake, “Chemoinformatics—predicting the physicochem- ical properties of ”drug-like” molecules,” Current Opinion in Biotechnology, vol. 11, no. 1, pp. 104–107, 2000. [22] D. Butina, M. D. Segall, and K. Frankcombe, “Predicting ADME properties in silico: methods and models,” Drug Dis- covery Today, vol. 7, no. 11, pp. S83–S88, 2002. [23] S. Agatonovic-Kustrin and R. Beresford, “Basic concepts of artiﬁcial neural network (ANN) modeling and its application in pharmaceutical research,” Journal of Pharmaceutical and Biomedical Analysis, vol. 22, no. 5, pp. 717–727, 2000. [24] I. Solomon, N. Maharshak, G. Chechik et al., “Applying an artiﬁcial neural network to warfarin maintenance dose prediction,” Israel Medical Association Journal, vol. 6, no. 12, pp. 732–735, 2004. [25] B. W. Corrigan, P. R. Mayo, and F. Jamali, “Application of a neural network for gentamicin concentration prediction in a general hospital population,” Therapeutic Drug Monitoring, vol. 19, no. 1, pp. 25–28, 1997. [26] C. W. Lim, S. Fujiwara, F. Yamashita, and M. Hashida, “Pre- diction of human skin permeability using a combination of molecular orbital calculations and artiﬁcial neural network,” Biological and Pharmaceutical Bulletin, vol. 25, no. 3, pp. 361– 366, 2002. [27] S. Dra˘ghici and R. B. Potter, “Predicting HIV drug resistance with neural networks,” Bioinformatics, vol. 19, no. 1, pp. 98– 107, 2003. [28] I. V. Tetko, “The WWW as a tool to obtain molecular parameters,” Mini Reviews in Medicinal Chemistry, vol. 3, no. 8, pp. 809–820, 2003. [29] I. V. Tetko, V. Y. Tanchuk, and A. E. P. Villa, “Prediction of n-octanol/water partition coeﬃcients from PHYSPROP database using artiﬁcial neural networks and E-state indices,” Journal of Chemical Information and Computer Sciences, vol. 41, no. 3–6, pp. 1407–1421, 2001. [30] A. Arnot, W. Meylan, J. Tunkel et al., “A quantitative structure- activity relationship for predicting metabolic biotransfor- mation rates for organic chemicals in ﬁsh,” Environmental Toxicology and Chemistry, vol. 28, no. 6, pp. 1168–1177, 2009. [31] A. Arnot and F. A. P. C. Gobas, “A review of bioconcentration factor (BCF) and bioaccumulation factor (BAF) assessments for organic chemicals in ﬁsh,” Environmental Reviews, vol. 14, no. 4, pp. 257–297, 2006. [32] C. Cobelli, E. R. Carson, L. Finkelstein, and M. S. Leaning, “Validation of simple and complex models in physiology and medicine,” The American Journal of Physiology, vol. 246, no. 2, pp. R259–266, 1984. [33] R. Mannhold, G. I. Poda, C. Ostermann, and I. V. Tetko, “Calculation of molecular lipophilicity: state-of-the-art and